The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The overall goal of this study is to develop a platform for both large-scale chemoprevention
trials and real-world chemoprevention studies for colorectal cancer (CRC) prevention. The
specific objectives of this proof of concept study are to:
1. Evaluate the feasibility of a real-world chemoprevention agent (CPA) intervention
(3-months of daily low-dose acetylsalicylic (ASA)) in participants at increased risk for
CRC (one or more high-risk adenomas removed during colonoscopy) based on participant
uptake, adherence (days taking CPA), and adverse events;
2. Evaluate factors related to uptake and adherence of ASA using validated surveys and
interviews.
Phase:
Phase 2
Details
Lead Sponsor:
University of Calgary
Collaborators:
Canadian Cancer Society (CCS) Canadian Institutes of Health Research (CIHR)